Physician profile
David W Tybor
NPI 1912064957
$2,851.01
in general payments reported to CMS, 2019-2025
20 companies · $58.68 in 2025
The $58.68 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $201 · 2021: $435 · 2022: $700 · 2023: $494 · 2024: $425 · 2025: $58.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Entertainment: $14.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.41 |
| Entertainment | $14.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $419.31 | 2019-2022 | |
| Biotissue Holdings INC. | $397.42 | 2019-2024 | |
| Abbvie INC. | $312.65 | 2022-2025 | Lumigan, Durysta, Vuity |
| Bausch & Lomb Americas INC. | $258.54 | 2022-2025 | Xiidra, Miebo, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $205.20 | 2019-2021 | |
| Rxsight INC | $173.58 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Alcon Vision LLC | $170.66 | 2019-2025 | Total30, Tryptyr, Dailies Total1 |
| Sight Sciences, INC. | $159.61 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $146.63 | 2019-2022 | |
| Visioneering Technologies, INC. | $130.33 | 2019 | |
| Coopervision INC. | $127.36 | 2019-2024 | Myday Contact Lens |
| Eyevance Pharmaceuticals LLC | $87.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $66.78 | 2021-2022 | |
| Thea Pharma INC. | $45.83 | 2022-2024 | Iyuzeh |
| Oyster Point Pharma, INC. | $39.46 | 2022-2023 | Tyrvaya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $33.54 | 2021-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $24.78 | 2020 | |
| Sun Pharmaceutical Industries INC. | $23.88 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $15.45 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tybor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.